Published in Biotech Law Weekly, February 23rd, 2007
These data were invited for presentation at an international cell and gene therapy conference and were reported by Dr. Robert E. Sobol, Introgen's senior vice president of medical and scientific affairs, in a presentation titled "Critical Path and Oncology Biomarker Qualification Initiatives for the Late-Phase Development of ADVEXIN p53 Tumor Suppressor Therapy."
"We have previously reported that ADVEXIN therapy in recurrent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.